Entasis Therapeutics Holdings Inc. (ETTX) News

Entasis Therapeutics Holdings Inc. (ETTX): $2.19

-0.01 (-0.45%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter ETTX News Items

ETTX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest ETTX News From Around the Web

Below are the latest news stories about ENTASIS THERAPEUTICS HOLDINGS INC that investors may wish to consider to help them evaluate ETTX as an investment opportunity.

Entasis Therapeutics Presents Data on Sulbactam-Durlobactam and ETX0462 at 2022 ASM Microbe Annual Conference

WALTHAM, Mass., June 09, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced multiple presentations at the American Society for Microbiology (ASM) annual Microbe conference, taking place June 9-13, 2022, in Washington, DC. Entasis is presenting data on sulbactam-durlobactam (SUL-DUR), an investigational drug in development for the treat

Yahoo | June 9, 2022

Biotech Stock Roundup: ETTX Up on Acquisition Deal, REGN Offers Updates

Regulatory updates and acquisition news from Entasis (ETTX) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.

Yahoo | May 25, 2022

ENTASIS ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of ETTX and Encourages Investors to Contact the Firm

NEW YORK, May 24, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Innoviva, Inc. (NASDAQ: INVA).

GlobeNewswire | May 24, 2022

Entasis (ETTX) Stock Rises on Buyout Offer From Innoviva

Innoviva (INVA) is set to acquire Entasis (ETTX) for $2.20 per share in cash. The transaction is likely to close by third-quarter 2022.

Yahoo | May 24, 2022

AstraZeneca spinout, based in Waltham, acquired at 60% premium

Entasis Therapeutics, an antibiotics developer that spun out of AstraZeneca plc in 2015, has been acquired by its majority shareholder, California's Innoviva Inc.

Yahoo | May 24, 2022

Innoviva to acquire Entasis Therapeutics for $2.20/share

Innoviva (INVA) and Entasis Therapeutics Holdings (ETTX) has entered into a definitive merger agreement under which Innoviva is to acquire all of the outstanding shares of Entasis at…

Seeking Alpha | May 23, 2022

Innoviva Acquires AstraZeneca-Spin Off At $2.20/Share

Innoviva Inc (NASDAQ: INVA ) has agreed to acquire Entasis Therapeutics Holdings Inc (NASDAQ: ETTX ) at $2.20 per share in cash. Innoviva currently owns approximately 60% of the outstanding shares of Entasis common stock. The acquisition consideration values Entasis'' equity at $113 million on a fully diluted basis. "This acquisition will build upon our overall strategy to acquire … Full story available on Benzinga.com

Benzinga | May 23, 2022

GeoVax, Entasis top healthcare gainers, while Nymox, Evoke Pharma lead losers'' pack

GeoVax Labs GOVX +39%. Entasis Therapeutics ETTX +21%. Nymox Pharmaceutical NYMX -67%. Evoke Pharma EVOK -21%.

Seeking Alpha | May 23, 2022

Innoviva to Acquire Entasis Therapeutics

BURLINGAME, Calif. & WALTHAM, Mass., May 23, 2022--Innoviva, Inc. (Nasdaq: INVA) ("Innoviva"), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, and Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX) ("Entasis"), an advanced late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the companies have entered into a definitive merger agreement under which

Yahoo | May 23, 2022

Antibiotic resistance efforts get a boost as CARB-X gets $370M

Kevin Outterson has spent the better part of the last year in conversations with CARB-X's previous backers. Now, those efforts have yielded fruit: The organization has another $370 million to invest in research targeting drug-resistant bacteria.

Yahoo | May 19, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5295 seconds.